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Abstract 
Background: This study aimed to investigate whether the DNA methylation of human ovarian carcinoma stromal 
progenitor cells (OCSPCs) could promote the tumorigenesis of ovarian carcinoma.
Methods: OCSPCs were first isolated from fresh tumor tissues and ascites of ovarian cancer patients. In vivo and 
in vitro experiments on the effect of the OCSPCs on tumorigenesis and the effects of DNA demethylation on the 
OCSPCs were then performed.
Results: The OCSPCs possessed self‑renewal and multipotent differentiation capacity with elevated expressions of 
OCT4, NANOG, BMP2, BMP4, Rex‑1, AC133 and TGF‑β. The OCSPCs, when combined with tumor cells in vivo could 
promote tumor growth. The methylation profiles of tumor suppressor genes (TSGs) were significantly higher in the 
OCSPCs than in ovarian cancer cells (p < 0.001). 5‑aza‑2‑dC could alter the methylation levels of TSGs in OCSPCs 
and also inhibit the tumor promoting capabilities of the OCSPCs by decreasing the proliferation of tumors cells. The 
expression levels of TSGs were re‑expressed by 5‑aza‑2‑dC to inhibit the self‑renewal and growth of OCSPCs.
Conclusions: OCSPCs with decreased TSG expressions in the ovarian tumor microenvironment were able to pro‑
mote tumorigenesis which could be reversed by DNA demethylation. DNA demethylation reversing the expression of 
TSGs in OCSPCs may represent a potential therapeutic target for ovarian cancer.
Keywords: Tumorigenesis, Ovarian carcinoma stromal progenitor cells, 5‑aza‑2‑deoxycytidine, Tumor suppressor 
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© 2015 Ho et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Ovarian cancer is the fifth leading cause of death from 
cancer in Western countries, and the leading cause of 
death from gynecologic cancer [1]. Most cases of ovar-
ian cancer are high-grade serous carcinoma involv-
ing concurrent serous tubal intraepithelial carcinoma, 
which supports a clonal relationship characterized by 
TP53 mutations [2–5]. Efforts at improving survival have 
focused on the early detection of ovarian cancer and on 
the development of new chemotherapeutic drugs. There-
fore, it is essential to understand the initiation and mech-
anism underlying the progression of ovarian cancer.
At least one-third of epithelial ovarian cancers are 
associated with ascites, a massive amount of exudative 
fluid with a cellular fraction consisting mainly of cancer 
cells, lymphocytes, mesothelial cells, and soluble factors. 
Ascites is thought to contribute to the spreading of can-
cer cells to metastatic sites [6–8]. Stromal cells heteroge-
neously consist of fibroblasts, endothelial or mesothelial 
cells, adipocytes or adipose tissue-derived stromal cells, 
bone marrow-derived stem cells, and immunocytes. They 
can enhance tumor growth via secretion of growth or 
pro-angiogenetic factors such as fibroblast growth factor, 
vascular endothelial growth factor, and epidermal growth 
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factor [9, 10]. Although ascites is a common symptom 
in patients with ovarian cancer, the origin of malignant 
ascitic fluid and its relationship to tumor progression are 
still poorly understood.
Recently, distinct DNA methylation profiles in ovar-
ian serous neoplasms and their association with ovarian 
carcinogenesis and clinical outcome have been reported 
[11, 12]. The progression of ovarian cancer is associated 
with the accumulation of aberrant promoter methyla-
tion [12, 13], leading to transcriptional silencing of tumor 
suppressor genes (TSGs). Evidence suggests that genetic 
and non-genetic alterations in both ovarian surface epi-
thelium and the surrounding stromal compartments 
may determine the phenotypic characteristics and func-
tional performance of these cells. Preclinical and clini-
cal studies have shown that hypomethylating agents can 
reverse platinum resistance in ovarian cancer cell lines 
and tumor xenografts [14–18]. In addition, aberrant TSG 
hypermethylation has been shown to be sufficient to 
transform somatic stem cells to fully malignant cells with 
cancer stem/initiating properties [19].
Mesenchymal stem cells (MSCs) can be recruited to 
the tumor microenvironment and are known as tumor-
associated MSCs. Normal human bone marrow-derived 
MSCs can differentiate into tumor-associated fibro-
blasts which produce numerous growth factors to sup-
port angiogenesis, tumor growth and metastasis [20–22]. 
In addition, ovarian carcinoma-associated MSCs have 
been shown to promote tumor growth by increasing the 
number of cancer stem cells [23]. Thus, it is important 
to understand the phenotypic alteration of tumor-asso-
ciated MSCs within the tumor and their contribution 
to tumorigenesis in patients with ovarian carcinoma. 
In this study, we isolated two types of ovarian cancer 
stromal progenitor cells (OCSPCs) (epithelial-like and 
mesenchymal-like cells) from ascites and cancerous tis-
sues [24]. Cultured in vitro, these OCSPCs displayed the 
potential for self-renewal and long-term proliferation, 
and expressed the typical cancer stem/progenitor cell 
markers CD44high, CD24low, and AC133+ by in  vitro 
culture. These OCSPCs also demonstrated high BMP-2, 
BMP4, TGF-b, Rex-1, and AC133 early gene expression, 
and expressed EGFR, integrin α2β1, CD146, and Flt-
4, which are highly associated with tumorigenesis and 
metastasis. The epithelial-like OCSPCs demonstrated 
higher cytokeratin 18 and E-cadherin expression than 
the mesenchymal type cells. The mesenchymal type cells, 
in contrast, demonstrated higher AC133, CD73, CD105, 
CD117, EGFR, integrin a2b1, and CD146 surface marker 
expression than he epithelial type cells [24]. Genes meth-
ylation was significantly higher in the OCSPCs from 
ascites than that from tissues. OCSPCs can contribute to 
the progression of ovarian cancer accompanied by meth-
ylation of tumor suppressor genes.
Methods
Ascites and cancerous tissue sample collection 
from patients with epithelial ovarian cancer
The Institutional Review Board of our hospital approved 
the study protocol and all patients provided informed 
consent before the samples were collected. Tumor and 
ascites samples obtained during surgery were imme-
diately taken to the laboratory for processing. Normal 
ovarian tissues were obtained from histologically-proven 
normal ovaries from patients with early-stage ovarian 
cancer.
In vitro isolation and culture of OCSPCs from ascites 
and cancerous tissues
OCSPCs from ascites and cancerous tissues were iso-
lated as described previously [24]. Briefly, the cells were 
pelleted by centrifugation at room temperature for 5 min 
at 1500  rpm for mesenchymal-like OCSPCs. For the 
selection of epithelial-like OCSPCs, Ficoll-Paque (GE 
Healthcare Life Sciences) gradient was applied to isolate 
mononuclear cells was and then washed with 2 mmol/L 
of EDTA. Total 3 ×  106 cells were re-suspended in cul-
ture medium [basal medium A: Dulbecco’s modified 
Eagle’s medium (DMEM/F12) supplemented with 10  % 
FBS (Hyclone), 10  ng/mL EGF and 10  ng/mL FGF-b1; 
basal medium B: M199 medium supplemented with 10 % 
FBS, 20 ng/mL EGF and 0.4 μg/mL hydrocortisone]. The 
cells were maintained in a humidified chamber with 5 % 
CO2 at 37 °C, and the media were refreshed every 3 days. 
OCSPCs at passage 4 were harvested for further experi-
ments. Normal or cancerous ovarian tissue samples were 
minced in HBSS (Invitrogen; Grand Island, NY, USA), 
mixed with 1 mg/ml of collagenase 1A (Sigma) at 37  °C 
for 60 min, and then filtered through a 70-μm nylon mesh 
to remove the undigested tissue pieces and centrifuged to 
obtain cell pellets.
Differentiating capabilities of ascites‑derived OCSPCs
The protocols for adipogenic, osteogenic, chondrogenic, 
and neurogenic differentiation of the mesenchymal-like 
OCSPCs were as described previously [25]. The adi-
pogenic differentiation medium was DMEM/LG with 
10 % FBS, 0.5 mM isobutyl-methylxanthine, 1 μM dexa-
methasone, 10  μM insulin and 200  μM indomethacin. 
The osteogenic medium was DMEM/LG with 10 % FBS, 
0.1  μM dexamethasone, 50  μM ascorbate-2-phosphate, 
and 10  mM β-glycerolphosphate. The chondrogenic 
medium was DMEM/LG with 1 % FBS, 6.25 μg/ml insu-
lin, 10 ng/ml TGF-β1, and 50 nM ascorbate-2-phosphate. 
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The neurogenic differentiation medium was DMEM/LG 
supplemented with 5 μg/ml insulin, 200 uM indometha-
cin, and 0.5 mM isobutyl-methylxanthine. The cells were 
fixed for histochemical staining after 14  days of adipo-
genic, osteogenic or chondrogenic differentiation, and 
the neurogenic-lineage cells were fixed for histochemical 
analysis after 28  days of differentiation. The angiogenic 
differentiation of the OCSPCs was analyzed by capil-
lary formation using Matrigel. After being cultured for 
7  days in EGM-2, the cells were trypsinized and plated 
onto a Matrigel coated (Matrigel:M199  =  1:1) 24-well 
plate. Capillary-like structures were observed by optical 
microscopy at the indicated time points.
Flow cytometric analysis
Specific marker expressions in the OCSPCs were 
analyzed using flow cytometry (FACSCalibur, BD 
Biosciences). Fluorescein isothiocyanate- or phyco-
erythrin-conjugated antibodies against CA125, integ-
rin α2β1, CD24, CD44, EGFR, CD105, CD34, CXCR4, 
SSEA1, SSEA3, SSEA4, Globo H, CD201, E-cadherin, 
AC133, CD73, CD90, CD117, CD146, CXCR4, PDGFR, 
NANOG, OCT3/4, cytokeratin 18, and FLT-4.
Polymerase chain reaction (PCR) and sequence analysis 
of TP53
Exons 1-8 (except 9-11) of entire coding region of TP53 
in both epithelial- and mesenchymal-like OCSPCs as well 
as ovarian cancer tissues were amplified and sequenced 
by PCR (Additional file 1: Table S1). The PCR products 
were subjected to electrophoresis on 2 % agarose gel, and 
BioEdit v7.1.3 software was used to analyze the DNA 
sequences. The obtained sequences were compared to 
published reference sequences (http://www.clinchem.
org/content/44/7/1397.long).
Immunocytochemistry of PAX8 and calretinin
Immunocytochemistry of both epithelial- and mesenchy-
mal-like OCSPCs was performed using a Ventana Bench-
mark automated stainer (Ventana, Tucson, AZ, USA) 
with primary Abs against PAX8 and calretinin.
Methylation‑specific multiplex ligation‑dependent probe 
amplification (MS‑MLPA) of TSGs
MS-MLPA using SALSA MLPA kits including ME001B 
and ME003-A1 (MRC-Holland, Amsterdam, Nether-
lands) as described previously [26]. The methylation ratio 
(M-ratio) was calculated by dividing the relative peak 
value or probe fraction of the ligation-digestion sample 
by the relative peak value of the corresponding undi-
gested ligation sample. M-ratio values of 0.00–0.29 were 
defined as being the absence of methylation. M-ratio 
values of 0.30–0.49 were defined as being mild methyla-
tion, 0.50–0.69 as moderate methylation, and >0.70 as 
extensive hypermethylation [27]. The cumulative meth-
ylation index (CMI) was calculated as the sum of the per-
centages of methylation for all genes [28].
Sodium bisulfite treatment and methylation specific‑PCR
Genomic DNA of the OCSPCs and tumors was isolated 
with a Genomic DNA kit (Geneaid Biotech, Bade City, 
Taiwan). The DNA was converted with sodium bisulfite 
using a CpGenome DNA modification kit (Millipore, 
MA, USA), purified and amplified by PCR with Ther-
moHotStart 2X Gold PCR Master mix (Applied Biosys-
tems) with primers (Additional file 2: Table S2) at 95 °C 
for 10 min, followed by 40 cycles of 95 °C for 30 s, 62 °C 
for 30 s, and 72 °C for 40 s, with a final extension at 72 °C 
for 10  min and holding at 4  °C. Bisulfite-modified, Sss 
I-treated normal lymphocyte DNA served as the positive 
methylated control, and bisulfite-treated normal lympho-
cyte DNA served as the unmethylated control.
RNA preparation and quantitative real time reverse 
transcriptase PCR (QRT‑RT‑PCR)
RNA was isolated by TriPure reagent (Roche), and stored 
at −80 °C prior to use. The quantity and quality of RNA 
were evaluated by spectrophotometric analysis. QRT-
PCR was performed to quantitate the transcription of a 
specific gene. Total RNA was converted to cDNA with a 
Superscript III-reverse transcriptase kit (Invitrogen), and 
amplified by PCR with QIAGEN designed primers (Addi-
tional file 2: Table S2) at 95 °C for 5 min, followed by 40 
cycles of 95 °C for 10 s, and 60 °C for 30 s. Roche Light 
Cycler Software 4.05 was used to analyze the data which 
were expressed as the mean of the expression level of the 
gene normalized by the GAPDH housekeeping gene.
QRT-PCR was performed to quantitate the effect of 
5-aza-2-dC on gene expression. The OCSPCs were first 
treated with 10 μM of 5-aza-2-dC (Sigma, St. Louis, MO, 
USA). QRT-PCR was performed using an ABI Prism 
7300 Sequence Detection System (Applied Biosystems) 
with Taqman Gene Expression Assay Hs00369360g1 and 
the primers as described above at 50 °C for 2 min, 95 °C 
for 10 min, and then 40 cycles of 95 °C for 15 s and 60 °C 
for 1 min. The interpolated number (Ct) of cycles to reach 
a fixed threshold above the background noise was used to 
quantify amplification.
Tumorsphere formation of OCSPCs
Adherent mesenchymal- or epithelial-like OCSPCs were 
cultured in DMEM/F12 containing 20  ng/mL bFGF, 
20 ng/mL EGF, 10 ng/mL IGF, and 2 % B27 (Invitrogen, 
Carlsbad, CA, USA) with or without 5-aza-2-dC. The 
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number of spheres was counted after 7  days under an 
Olympus light microscope. The tumorspheres obtained 
on 14 days were then harvested for FACS analysis.
SKOV3 and SKOV3‑Luc cell lines
The SKOV3 cells primarily obtained from ATCC were 
gifted by Professor CL Chang (Mackay-Memorial Hos-
pital, Taipei, Taiwan), and SKOV3-Luc cells which were 
stably transduced with a luciferase-expressing lentivirus 
were used. The SKOV3 and SKOV3-luc cell lines were 
tested with human identification by STR marker to con-
firm the Cell line authentication. SKOV3 and SKOV3-luc 
cells were confirmed with ATCC Cell Bank DNA Pro-
file (STR), and CSF1PO (11,11), TH01 (9,9.3), D13S317 
(8,11), D16S539 (12,12), vWA (17,18), TPOX (8,11), 
Amelogenin (X,X), and D5S818 (11,11) markers with 
perfect match. Only the SKOV3-luc cells revealed a peak 
at D7S820 (13,14).
In vivo animal experiments and tumor imaging
NOD/SCID mice were purchased from the National 
Animal Center (Taipei, Taiwan), and all experiments 
were approved by the Institutional Animal Care and 
Use Committee of Cathay General Hospital. The experi-
ments (4 mice/group) were carried out with 1  ×  106 
SKOV3-Luc cells alone or a 1:1 mixture of SKOV3-Luc 
cells with OCSPCs or normal ovarian stromal progenitor 
cells (NOSPCs) (either epithelial- or mesenchymal-like). 
Tumor growth was measured using calipers, and volumes 
were calculated based on the modified ellipsoid formula 
(L × W × W/2). Bioluminescence optical images (Xeno-
gen IVIS 2000, Caliper Life Sciences) were obtained on 
day 12, 16, 22, 25, and 39 after tumor cell injection.
Statistical analysis
Statistical analyses were performed using SPSS statistical 
software (SPSS 16.0.1 for Windows, Chicago, IL, USA). 
The frequencies of promoter methylation of 40 genes 
were compared using the Chi square test. The CMI and 
methylation of individual genes and the mRNA expres-
sion levels were assessed using the Mann–Whitney U 
test. A p value less than 0.05 was defined as being statisti-
cally significant.
Results
The expressions of differential markers in OCSPCs 
and NOSPCs
The OCSPCs showed higher expressions of CA125, Flt4, 
AC133, CD34, CD117, and CD146, but lower expres-
sions of CD24, NANOG and OCT3/4 compared to the 
NOSPCs (Fig.  1a). The expression levels of BMP2 and 
BMP4 were also higher in the OCSPCs (Fig.  1b). The 
OCSPCs also highly expressed cell cycle-related genes 
such as those encoding P21, P27, P53, cyclin D, and Bcl-
xL (Fig.  1b). The epithelial-like OCSPCs showed higher 
expressions of cytokeratin 18 and E-cadherin than the 
mesenchymal-like OCSPCs (Fig.  1a). In contrast, the 
mesenchymal-like OCSPCs had higher expressions of 
AC133, CD117, integrin α2β1, CD146, CXCR4, NANOG 
and OCT3/4 than the epithelial-like OCSPCs (Fig. 1a).
Both epithelial‑ and mesenchymal‑like OCSPCs originated 
from mesothelial cells not ovarian cancer cells
Isolated epithelial- and mesenchymal-like OCSPCs in 
ascites and cancerous tissues were further analyzed to 
differentiate their origin. The G281T point mutation in 
exon 8 of TP53 (aspartic acid changed to tyrosine) was 
detected in the cancerous tissues (Additional file 3: Fig-
ure S1). However, only wild-type TP53 of both epithe-
lial- and mesenchymal-like OCSPCs was noted. This 
indicated that the non-cancerous origin of the OCSPCs. 
Furthermore, immunocytochemical analysis demon-
strated strong expressions of ovarian epithelial cancer 
cell and mesothelial cell markers, PAX8 and calretinin, in 
both types of OCSPC (Fig. 2a), implicating that a meso-
thelial origin of the OCSPCs was most likely.
MS‑MLPA profiles of TSG methylation in the OCSPCs 
and ovarian cancer cells
DNA methylation of TSGs in the OCSPCs and ovarian 
cancer cells was analyzed by MS-MLPA. The CMI among 
40 TSGs was significantly higher in the OCSPCs from 
ascites than that from tissues (p < 0.001, Additional file 4: 
Table S3). The gene with the most frequent hypermeth-
ylation in the OCSPCs from ascites was CDKN2B (50 %), 
followed by RASSFIA (44  %) and DLC1 (44  %) (Addi-
tional file  5: Table  S4). Whereas, the most frequently 
hypermethylated gene detected in the OCSPCs from can-
cerous tissues was CCND2 (50 %), followed by CDKN2B 
(25  %) and DLC1 (25  %) (Additional file  5: Table  S4). 
Among these 40 genes, none was found to be methyl-
ated in the NOSPCs. The most frequently hypermeth-
ylated genes in the bulk tumors were CDKN2B (63  %), 
RASSFIA (50  %), and DLC1 (38  %) (Additional file  5: 
Table S4). In addition, the CMIs of CDKN2B, RASSFIA, 
DLC1 and CCND2 in the OCSPCs from ascites were sig-
nificantly higher than those in the OCSPCs from tissues 
(p = 0.001) or bulk tumor cells (p = 0.038).
Expression levels of CDKN2B, RASSFIA, DLC1 and CCND2 
genes in the OCSPCs and ovarian cancerous tissues
To clarify whether the methylation status was correlated 
with the expression levels of CCND2, RASSF1A, DLC1 
and CDKN2B, the mRNA levels of these genes were 
quantified by QRT-PCR. The mRNA levels of CCND2 
(0.374 ±  0.433 vs. 0.733 ±  0.583, p =  0.012, student’s t 
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test) and CDKN2B (0.143  ±  0.048 vs. 1.172  ±  0.740, 
p  <  0.001, student’s t test), but not RASSF1A 
(1.635  ±  0.433 vs. 2.150  ±  1.630, p  =  0.229, student’s 
t test) and DLC1 (1.269  ±  0.502 vs. 1.985  ±  1.099, 
p  =  0.085, student’s t test), were significantly lower in 
the OCSPCs from ascites than those from bulk tumor 
tissues. When stratifying the OCSPCs by origin, the 
mRNA levels of CCND2 (0.074 ± 0.06 vs. 0.733 ± 0.583, 
p < 0.001, student’s t test), RASSF1A (0.553 ± 0.164 vs. 
2.150  ±  1.630, p  <  0.001, student t test) and CDKN2B 
(0.153 ±  0.056 vs. 1.172 ±  0.740, p  <  0.001, student’s t 
test), but not DLC1 (1.471  ±  0.573 vs. 1.985  ±  1.099, 
p = 0.374, student t test) were significantly lower in the 
epithelial-like OCSPCs from ascites than those from bulk 
tumor tissues. Whereas, the mRNA levels of CDKN2B 
(0.128 ±  0.034 vs. 1.172 ±  0.740, p  <  0.001, student’s t 
test) were significantly lower in the mesenchymal-like 
OCSPCs from ascites than those from bulk tumor tis-
sues, but CCND2 (0.824  ±  0.325 vs. 0.733  ±  0.583, 
p  =  0.441, student’s t test), RASSF1A (2.987  ±  0.872 
vs. 2.150 ± 1.630, p = 0.066, student’s t test) and DLC1 
(1.068 ±  0.357 vs. 1.985 ±  1.099, p =  0.051, student’s t 
test) remained similar in the mesenchymal-like OCSPCs 
from ascites than those from bulk tumor tissues. The 
mRNA levels of these four genes were significantly 
lower in the epithelial-like OCSPCs (0.604  ±  0.588 vs. 
1.550 ± 1.280, p = 0.002, student’s t test) than those in 
the mesenchymal-like OCSPCs.
In addition, the mRNA levels of these four genes 
were significantly lower in the OCSPCs from ascites 
(1.038 ±  1.069 vs. 1.212 ±  0.902, p =  0.022, student’s t 
test) than those in the OCSPCs from tissues or those in 
the bulk tumor tissues (1.038 ± 1.069 vs. 1.509 ± 1.279, 
p < 0.001, student’s t test).
Epithelial‑like but not mesenchymal‑like OCSPCs exhibited 
epithelial‑mesenchymal transition (EMT) and formed 
tumorspheres
Both epithelial- and mesenchymal-like OCSPCs were 
able to form non-adherent, aggregated spheroids in low 
Fig. 1 a The percentages of cells expressing typical cancer stem/progenitor cell markers and embryonic stem cell markers in the epithelial‑ and 
mesenchymal‑like OCSPCs and NOSPCs analyzed by flow cytometry. b The expression levels of BMP‑2, BMP4, TGF‑β, Rex‑1, RB, and AC133 cell cycle‑
related genes in P21, P27, and P53, cyclin D, Bcl‑xL, and Bax in the epithelial and mesenchymal types of OCSPCs and NOSPCs by RT‑PCR
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adherent discs supplemented with specific growth factors 
and could be maintained for at least 7 days (Fig. 2b). Only 
integrin α2β1 significantly increased in the cells within the 
tumorsphere compared to those in the original adher-
ent OCSPCs (Figs. 1a, 2c). However, a higher expression 
of E-cadherin was detected in adherent epithelial-like 
OCSPCs than in the cells that formed non-adherent 
OCSPC spheroids (93.7 vs. 75  %) (Figs.  1a, 2c). How-
ever, similarly lower levels of E-cadherin were found in 
the mesenchymal-like non-adherent spheroid cells and 
the adherent OCSPCs (Figs.  1a, 2c). Furthermore, the 
glycan cell surface molecules, stage-specific embryonic 
antigen SSEA3 and SSEA4, were also highly expressed 
in the non-adherent spheroid cells (Fig.  2c). When the 
Fig. 2 a Immunocytochemical analysis of PAX8 and Calretinin on both epithelial‑ and mesenchymal‑like OCSPCs. b Cell morphology of original 
adherent epithelial‑ and mesenchymal‑like OCSPCs and the respectively derived non‑adherent floating tumorspheres. c The percentages of cells 
expressing various surface markers on non‑adherent tumorspheres derived from either epithelial‑ or mesenchymal‑like 49th OCSPCs analyzed by 
flow cytometry. d The percentages of cells expressing various surface markers on 64th OCSPCs cultured in either adherence conditions (selective 
for epithelial‑ and mesenchymal‑like OCSPCs) or non‑adherent (tumorsphere culture) and the respectively derived non‑adherent tumorspheres 
analyzed by flow cytometry
Page 7 of 14Ho et al. J Transl Med  (2015) 13:367 
spheroids formed by both types of adherent OCSPCs 
were cultured for 14  days, the expression of E-cadherin 
decreased by at least fivefold (17.9 vs. 93.4  %), however 
vimentin increased by approximately 40-fold (83.1 vs. 
2.4 %) in non-adherent spheroid cells compared to those 
in adherent epithelial-like OCSPCs (Fig. 2d), implicating 
the occurrence of EMT. E-cadherin remained at a similar 
lower level in the mesenchymal-like non-adherent sphe-
roid cells and the adherent mesenchymal-like OCSPCs 
(Fig.  2d). The expressions of the other stemness mark-
ers including AC133, CD34, CD117, CXCR4, NANOG 
and OCT3/4 were also significantly increased in the 
non-adherent tumorspheres than those in the adherent 
OCSPCs (Fig. 2d).
Multipotent capability of the OCSPCs to differentiate 
into various cell lineages
The OCSPCs were further examined to see if they had the 
potential to produce different types of cells. The results 
showed that the mesenchymal-like OCSPCs had the 
capability to differentiate into multiple cell types includ-
ing myogenic (Fig.  3a), neurogenic (Fig.  3b), adipogenic 
(Fig. 3c), osteogenic (Fig. 3d), chondrogenic (Fig. 3d), and 
vascular (Fig. 3e) cells under different conditional culture 
media.
The OCSPCs promoted tumor growth in vivo
The influence of the OCSPCs on ovarian tumor growth 
was further evaluated with modified SKOV3 ovarian 
cancer cells, SKOV3-Luc cells carrying the luciferase 
reporter. The representative chemiluminescent images 
of SKOV3-Luc tumor growth in the various groups are 
shown in Fig.  4a. The mice that received SKOV3-Luc 
cells with epithelial-like OCSPCs demonstrated a con-
sistent increase in luciferase activity compared with 
SKOV3-Luc cells alone, SKOV3-Luc cells with mesen-
chymal-like OCSPCs, and the SKOV3-Luc cells with 
NOSPCs (Fig. 4b). On day 39 after xenograft, the mean 
tumor sizes were largest in the mice that received SKOV3 
cells with the epithelial-like OCSPCs compared with the 
other groups (Fig. 4c). These data suggest that epithelial-
like OCSPCs can promote ovarian tumor growth. Beside, 
the histological analysis of these tumors was performed 
to reveal that all these tumors were similar to those in the 
histopathology of high grade serous adenocarcinoma of 
human ovarian cancer.
5‑aza‑2‑dC changed the expression profiles 
and reactivated TSGs in the OCSPCs
To investigate the impact of demethylation on the tumo-
rigenic promoting activity of OCSPCs, representative 
Fig. 3 Multiple cell‑lineage differentiation potential of OCSPCs. a Myofibroblast differentiation. The expressions of myofibroblast markers sSMA and 
vimentin. b Neurogenic differentiation. The neurogenic markers neuron‑specific class II β‑tubulin and nestin. c Adipogenic differentiation. Intracel‑
lular oil droplets were detected by Oil Red O staining. d Osteogenic and chondrogenic differentiation. Positive calcified extracellular matrix with von 
Kossa staining and cartilage ball formation. e Vascular differentiation. Vascular tube formation was noted on a Matrigel assay
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marker expressions were analyzed in cells treated with 
5-aza-2-dC. The OCSPCs treated with 5-aza-2-dC had 
higher levels of CD24, CD105, and CXCR4, but lower 
levels of AC133, CD34, CD90, CD117, EGFR, integrin 
α2β1, CD146, FLT4, NANOG, and OCT3/4 compared 
to the cells without treatment (Fig.  5a). In addition, the 
CMI among the 40 TSGs tested was significantly lower 
in the epithelial-like OCSPCs after 5-aza-2-dC treatment 
compared to those without treatment (p  <  0.001, Addi-
tional file 6: Table S5). However, the demethylating effect 
of 5-aza-2-dC was not detected in the mesenchymal-like 
OCSPCs, although demethylation (Fig. 5b) and increased 
RNA levels (Fig.  5c) of DLC1, CCND2, RASSF1A, and 
CDKN2B genes were identified in both the epithelial- 
and mesenchymal-like OCSPCs on day 4 or day 6 post-
exposure to 5-aza-2-dC.
5‑aza‑2‑dC altered self‑renewal, growth‑ 
and stemness‑related gene expressions in the 
OCSPCs and reduced the niche potential of OCSPCs 
for tumorigenicity of ovarian cancer
Neither mesenchymal- nor epithelial-like progenitor cells 
derived from malignant ascites had significant morpho-
logical changes upon 5-aza-2-dC treatment (Fig.  5d). 
Kinetic analysis demonstrated that the growth rates of 
the mesenchymal- or epithelial-like progenitor cells were 
reduced when treated with 5-aza-2-dC (Fig.  6a). The 
expressions of the stem-like cell surface markers includ-
ing AC133, CD34, CD117, EGFR, integrin α2β1, Flt4, and 
CD146 in the OCSPCs were decreased upon 5-aza-2-dC 
treatment (Fig. 5a). In addition, both the epithelial- and 
mesenchymal-like OCSPCs showed significantly reduced 
levels of TWIST1, HIF-1α, MDR1, and ABCG2 on 
Fig. 4 a Representative figures of chemiluminescent images of SKOV3‑Luc tumor growth in various groups. b Relative luciferase activities of 
SKOV‑3‑Luc tumors in various groups at day 12, 16, 22, 25 and 39. Controls received SKOV3‑Luc cells only. Normal represents NOSPCs, CA represents 
OCSPCs, Epi and Mes represent epithelial‑ or mesenchymal‑like cells, respectively. c Sizes of the SKOV‑3‑Luc tumors in various groups at day 39
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treatment with 5-aza-2-dC (Fig. 6b). The higher expres-
sion levels of MDR1 and ABCG2 efflux pumps may 
reflect increased drug resistance.
Exposure to 5-aza-2-dC also resulted in twofold 
decrease in the number of in vitro tumor spheres formed 
by the OCSPCs (Fig. 6c). The in vivo animal experiments 
revealed that the mice receiving SKOV3-Luc plus 5-aza-
2-dC-treated epithelial-like OCSPCs demonstrated a 
consistent decrease in luciferase activity compared to the 
mice receiving SKOV3-Luc plus epithelial-like OCSPCs 
without 5-aza-2-dC for up to 39 days (Fig. 4a, b). How-
ever, 5-aza-2-dC treatment of the mesenchymal-like 
OCSPCs did not affect their influence on the growth of 
SKOV3-Luc tumor cells in the xenograft mice. In addi-
tion, 5-aza-2-dC treatment reduced the ability of the 
epithelial-like OCSPCs to promote tumorigenicity of 
SKOV3-Luc cancer cells and inhibited sphere forma-
tion of these OCSPCs. However, 5-aza-2-dC treatment 
also suppressed the tumorigenicity of SKOV3 in a mouse 
model [29].
5‑aza‑2‑dC altered the expressions of genes related to EMT 
and drug resistance in the OCSPCs
To correlate the demethylating effect of 5-aza-2-dC with 
the expression levels of EMT- and drug resistance-related 
genes, tumors isolated from the xenograft mice were ana-
lyzed. The RNA levels of drug resistance-related genes 
MDR1 and ABCG2, and hypoxia-related genes HIF-1α 
and HIF-2α were reduced in tumors derived from SKOV3 
with 5-aza-2-dC-treated epithelial-like OCSPCs com-
pared to SKOV3 with epithelial-like OCSPCs without 
treatment, or with mesenchymal-like OCSPCs or normal 
Fig. 5 a The percentages of cells expressing various surface markers on OCSPCs treated with or without 5‑aza‑2‑dC for 4 or 6 days as analyzed 
by flow cytometry. b Methylation status of DLC1, CCND2, RASSF1A, and CDKN2B genes treated with 5‑aza‑2‑dC for 4 or 6 days by MS‑PCR. c The 
expressions of CCND2, CDKN2B, RASSF1A, and DLC1 in OCSPCs treated with 5‑aza‑2‑dC detected by quantitative real‑time RT‑PCR. d The morphol‑
ogy between mesenchymal or epithelial progenitor cells from malignant ascites treated with and without 5‑aza‑2‑dC
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progenitor cells (Fig.  6d). Sustained downregulation of 
key regulatory genes including TWIST, Slug and Snail, 
which promote the process of EMT, was decreased in the 
tumors generated by SKOV3 with 5-aza-2-dC-treated 
epithelial-like OCSPCs (Fig. 6d). These data support the 
hypothesis that epigenetic demethylating stem-like cells 
in the niche of ovarian cancer may reduce the tumori-
genicity of epithelial ovarian cancer, possibly through the 
ablation of the EMT.
Discussion
This is the first study to demonstrate that promoter 
methylation of TSGs not only in ovarian tumor tissues 
but also in cancer-associated stromal progenitor cells 
contributes to the progression of ovarian cancer. Given 
the present uncertainty regarding the precise phenotype 
of stromal progenitor cells, it is critical to understand the 
differences and similarities between stromal progenitor 
cells in primary tumors and in metastatic ascites. Our 
results showed that significantly decreased methylation 
levels correlated with higher expressions of certain TSGs 
(CCND2, RASSF1A, DLC1 and CDKN2B) in stromal 
progenitor cells from primary tumors compared to pro-
genitor cells isolated from ascites. This finding supports 
our hypothesis that high methylation of the promoters of 
TSGs in progenitor cells which lose tumor suppressive 
function may contribute to tumor progression.
The biological characteristics of metastatic stem cells 
differ from those of stem cells in the primary tumor 
[30]. The current study showed similar methylation pat-
terns in 40 TSGs between migrating stromal progenitor 
cells from ascites and those from primary tumor tis-
sues, however the methylation levels in these two types 
of cells were different. It has been speculated that the 
Fig. 6 a Growth kinetics of epithelial‑ and mesenchymal‑like OCSPCs derived from 28th, 34th and 35th OCSPCs treated with or without 5‑aza‑2‑dC 
for 4 or 6 days. b The expressions of genes relating to EMT and drug resistance in OCSPCs from ascites of ovarian cancer patients treated with or 
without 5‑aza‑2‑dC detected by quantitative real‑time RT‑PCR. c Bar figure of the number of tumor spheres in epithelial‑ and mesenchymal‑like 
OCSPCs treated with or without 5‑aza‑2‑dC. d Quantitative real‑time RT‑PCR analysis of the expressions of drug resistance, EMT and hypoxia‑related 
genes in tumors isolated from xenograft mice of various groups
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malignant progression of stationary stromal progenitor 
cells from primary tumor tissues is through transforma-
tion into invasive and then migratory stromal progeni-
tor cells from ascites which is influenced by significantly 
increasing methylation of specific TSGs. In this study, 
most of the 40 TSGs were defined as being polycomb-
group genes, and the CMI among the 40 TSGs was sig-
nificantly higher in stromal progenitor cells from ascites 
than those from tissues (p < 0.001). The most frequently 
hypermethylated genes in stromal progenitor cells from 
ascites and corresponding bulk tumor tissues from the 
patients with serous ovarian cancer at an advanced stage 
were CDKN2B, RASSFIA, DLC1, and CCND2. However, 
the CMIs of these four genes in stromal progenitor cells 
from ascites were significantly higher than those from 
tissues (p =  0.001) and bulk tumor cells (p < 0.05), and 
were inversely correlated with those of mRNA expression 
levels. Interestingly, the mRNA levels of the four genes 
were significantly lower in the epithelial-like stromal pro-
genitor cells from ascites and tissues than those in the 
mesenchymal-like progenitor cells (p = 0.009).
The reversal of promoter DNA hypermethylation with 
restoration of the expressions of silenced genes is an 
attractive cancer therapy approach. Tsai et  al. reported 
that transient low doses of DNA-demethylating agents 
exert durable antitumor effects on leukemia and breast 
cancer cells [31]. In addition, targeting the androgen 
receptor promoter in prostate stem/progenitor cells with 
5-aza-2-dC has been reported to suppress prostate tumo-
rigenesis [32]. It is well known that DNA methylation is 
one of the epigenetic mechanisms regulating the expres-
sion of stemness genes [33, 34] and the in vitro promo-
tion of tumorsphere growth of cancer-associated MSCs 
[23]. To investigate whether 5-aza-2-dC could also affect 
the stemness of the identified stromal progenitor cells, 
QRT-PCR and flow cytometry analysis were used to char-
acterize the expressions of OCT3/4 and NANOG in the 
OCSPCs. The results showed that the stromal progenitor 
cells had multipotent differentiation abilities (Fig. 3) with 
relatively abundant expressions (40–50  %) of OCT3/4 
and NANOG which were significantly decreased after 
treatment with 5-aza-2-dC (Fig. 1a).
Our in  vitro and in  vivo experimental results demon-
strated that 5-aza-2-dC inhibited the promoting capa-
bility of stromal progenitor cells for tumor growth by 
decreasing the proliferation of epithelial tumors cells and 
altering the methylation levels of TSGs in the stromal 
progenitor cells. Taken together, the demethylating agent, 
5-aza-2-dC, reduced the growth rate and the expres-
sions of stemness genes in human OCSPCs. To inves-
tigate whether a demethylating agent could also affect 
the behavior of these cancer stromal progenitor cells, 
5-aza-2-dC was used to examine the expressions of EMT- 
and drug-resistance genes. Our results showed that these 
stromal progenitor cells had significantly higher levels of 
TWIST1, Slug (Snai2), Snail (Snai1), MDR1 (ABCB1), 
and ABCG2 genes, which are involved in the EMT and 
drug resistance, than those in normal controls (data not 
shown).
The antitumor responses we demonstrated may involve 
a resetting of the abnormal epigenetic status in stromal 
progenitor cells for their interaction with cancer cells. 
It is important to note that altered gene expression pat-
terns were accompanied by antitumor effects, and 5-aza-
2-dC treatment did not kill the cells. Thus, 5-aza-2-dC 
may cause sustained alterations in multiple key pathways 
involved in tumorgenesis, such as downregulation of the 
EMT, stemness, and drug resistance-related genes, and 
this effect may continue even after treatment is stopped. 
This finding may help in the development of a therapeutic 
approach for ovarian cancer treatment. Indeed, targeting 
stem/progenitor cells has emerged as a novel potential 
approach to battle ovarian cancer [34]. The advantages 
of using 5-aza-2-dC to target stromal progenitor cells 
include effectively suppressing their self-renewal/prolif-
eration ability and decreasing the proliferation of tumors 
cells. In addition, few side effects have been reported 
compared to the toxicity induced by other approaches 
to target stem/progenitor cells [35, 36], and the durable 
inhibition of tumor growth (lasting for at least 6  weeks 
in this study). Importantly, this approach can be used as 
combination therapy with conventional cytotoxic drugs 
or as maintenance therapy, suppressing most of the 
tumor cells containing stromal progenitor cells yet over-
coming drug resistance of stem/progenitor cells and res-
cuing TSG function.
Accumulating evidence indicates that prostate cancer 
and metastasis-initiating cells expressing stem-like mark-
ers including CD133+, CD44high, ALDhigh, ABCG2+ and 
CXCR4+high and endowed with a high self-renewal abil-
ity are critical for prostate cancer progression, metastasis 
and resistance to current clinical therapies [32, 37]. In this 
study, the OCSPCs expressed similar stem cell-like mark-
ers such as CD133+, CD44high and CXCR4+, and more 
specifically those expressing CD73high, CD117+, Flt4high, 
OCT3/4+, and NANOG+ possessed similar activity. 
Although numerous reports have focused on cancer 
stem cells in primary tumors [38], studies on cancer stem 
cells or MSCs and stromal progenitor cells in metasta-
sis have just begun to emerge. To date, very few studies 
have focused on human solid tumor-associated MSCs. 
Our previous study demonstrated that stromal progeni-
tor cells (tumor-associated stromal/progenitor cells) are 
present not only in human ovarian cancer tissues but also 
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in ascites [24], which is consistent with other reports that 
cancer-associated mesenchymal stem cells (CA-MSCs) 
are universally present in human ovarian cancer [23].
Our results support that mesenchymal-like cells are 
non-tumorigenic. However, epithelial-like cells may be 
tumorigenic with cancer stem-like characteristics which 
may enhance SKOV3-Luc tumor growth and recapitulate 
in the original tumor. Both cell populations in this study 
were selected and cultured as adherent cells and formed 
non-adherent aggregated tumor spheroids under suitable 
conditions. Importantly, the expression of E-cadherin 
was significantly down-regulated and vimentin expres-
sion was significantly upregulated when adherent epithe-
lial-like OCSPCs grew as non-adherent spheroids (94.5 
vs. 18.7 % and 2.1 vs. 83.1 %, respectively), while the lev-
els of these two genes remained unchanged in the mes-
enchymal-like non-adherent spheroids and the adherent 
mesenchymal-like OCSPCs. Moreover, non-adherent 
spheroid cells derived from adherent epithelial-like 
OCSPCs displayed a mesenchymal phenotype, similar to 
non-adherent spheroid cells from ascites. The epithelial-
like OCSPCs were shown to be capable of promoting 
tumor growth with an increasing tumor size, while the 
mesenchymal-like OCSPCs did not. These results suggest 
that epithelial-like progenitor cells may exhibit partial 
EMT and form tumorspheres which are more charac-
teristic of cancer stem-like cells under low adherent and 
serum free conditions. Besides, adherent epithelial-like 
stromal progenitor cells may originate and transform 
from non-adherent tumorspheres via the mesenchymal-
epithelial transition (MET) under serum induction with 
some loss of stemness. However, the mesenchymal-like 
progenitor cells did not follow the MET. The expressions 
of several mesenchymal cell surface markers (CD73, 
CD90, CD29, CD146, CD105 and integrin α2β1) and their 
ability to interact with tumor cells suggest that epithelial-
like progenitor cells exhibit similar features to those of 
MSCs.
Our results support that adherent epithelial-like stro-
mal progenitor cells may originate and transform from 
non-adherent tumorspheres via the mesenchymal-epi-
thelial transition (MET) under serum induction with 
some loss of stemness. However, it is better to validate 
our results by ex vivo experiment such as isolating non-
adherent tumorspheres from ascites of ovarian cancer 
patient, and then culturing them under serum induction.
A phase II trial concluded that epigenetic modula-
tion of DNA methylation restores platinum sensitiv-
ity in patients with platinum-resistant ovarian cancer, 
resulting in significant clinical activity as evidenced by 
a high response rate and prolonged progression-free 
survival [27, 39]. These findings support our hypothesis 
that demethylating agents not only restore sensitivity to 
platinum-based treatment in patients with platinum-
resistant ovarian cancer, but also restore the function of 
TSGs in stromal progenitor cells to help inhibit tumor 
growth. The expressions of MDR1 and ABCG2 were sig-
nificantly reduced in the stromal progenitor cells after 
5-aza-2-dC treatment, implying that this treatment may 
overcome drug resistance of stem/progenitor cells. The 
number of tumorspheres was also significantly reduced 
in stromal progenitor cells after 5-aza-2-dC treatment, 
further suggesting that this treatment may decrease cell 
stemness.
Conclusions
We have shown that OCSPCs possessed self-renewal 
and multipotent differentiation capacity by elevating the 
expressions of OCT4 and NANOG, BMP2, BMP4, Rex-
1, AC133 and TGF-β and with high methylation profiles 
of TSGs. Besides, OCSPCs, when combined with tumor 
cells in vivo, could promote tumor growth. The demeth-
ylating agent, 5-aza-dC, could alter the methylation levels 
of TSGs in OCSPCs and then inhibited the tumor pro-
moting capabilities of OCSPCs. OCSPCs can be potential 
targets for the treatment of ovarian carcinoma. The most 
value of the study is the new finding that the methylation 
levels of metastatic stem cells in ascites is different from 
those in primary tumor. To discover the biological char-
acteristics of metastatic stem cells needs more explora-
tions through experiments.
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